Dosing and switching strategies for quetiapine fumarate (Q34575702)

3 August 2017

1 reference

title

Dosing and switching strategies for quetiapine fumarate (English)

1 reference

3 August 2017

Andrew J Cutler

1

1 reference

3 August 2017

Jeffrey M Goldstein

series ordinal

2

1 reference

3 August 2017

John A Tumas

series ordinal

3

1 reference

3 August 2017

publication date

1 February 2002

1 reference

3 August 2017

published in

Clinical Therapeutics

1 reference

3 August 2017

volume

24

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

209-222

1 reference

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Seroquel and cognitive improvement in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Long-Term use of quetiapine in elderly patients with psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Efficacy of quetiapine in Parkinson's patients with psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Tolerability of atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Clinical pharmacokinetics of quetiapine: an atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Quetiapine alone and added to a mood stabilizer for serious mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Lamotrigine for the treatment of bipolar disorder: a clinical case series.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Clinical implications of clozapine discontinuation: report of an NIMH workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

Immediate recurrence of psychotic symptoms after discontinuation of clozapine: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2985018-4

7 January 2021

10.1016/S0149-2918(02)85018-4

Identifiers

DOI

1 reference

3 August 2017

1 reference